Covid-19 roundup: 34 AGs call for ‘march-in’ rights on remde­sivir; Hahn pleads with pub­lic to trust FDA's vac­cine re­view

A bi­par­ti­san group of 34 at­tor­neys gen­er­al have asked the fed­er­al gov­ern­ment to by­pass Gilead’s patent rights on remde­sivir and be­gin scal­ing and dis­trib­ut­ing the Covid-19 an­tivi­ral, or to al­low the states to do it them­selves.

In a let­ter to HHS sec­re­tary Alex Azar, the AGs ex­pressed frus­tra­tions over the $3,250 price tag Gilead placed on the the drug, cit­ing the fed­er­al fund­ing that went in­to its de­vel­op­ments. And they not­ed the sus­tained dif­fi­cul­ties hos­pi­tals have faced in get­ting sup­plies from ei­ther the Cal­i­for­nia biotech or their con­tract man­u­fac­tur­er Amerisource­Ber­gen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER